In vitro evidence that KLK14 regulates the components of the HGF/Met axis, pro-HGF and HGF-activator inhibitor 1A and 1B

References

Benaud, C., Dickson, R.B., and Lin, C.Y. (2001). Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur. J. Biochem. 268, 1439–1447.10.1046/j.1432-1327.2001.02016.xSearch in Google Scholar PubMed

Bergum, C. and List, K. (2010). Loss of the matriptase inhibitor HAI-2 during prostate cancer progression. Prostate 70, 1422–1428.10.1002/pros.21177Search in Google Scholar PubMed

Borgono, C.A., Michael, I.P., Komatsu, N., Jayakumar, A., Kapadia, R., Clayman, G.L., Sotiropoulou, G., and Diamandis, E.P. (2007a). A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J. Biol. Chem. 282, 3640–3652.10.1074/jbc.M607567200Search in Google Scholar PubMed

Borgono, C.A., Michael, I.P., Shaw, J.L., Luo, L.Y., Ghosh, M.C., Soosaipillai, A., Grass, L., Katsaros, D., and Diamandis, E.P. (2007b). Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J. Biol. Chem. 282, 2405–2422.10.1074/jbc.M608348200Search in Google Scholar PubMed

Brattsand, M., Stefansson, K., Lundh, C., Haasum, Y., and Egelrud, T. (2005). A proteolytic cascade of kallikreins in the stratum corneum. J. Invest. Dermatol. 124, 198–203.10.1111/j.0022-202X.2004.23547.xSearch in Google Scholar PubMed

Cecchi, F., Rabe, D.C., and Bottaro, D.P. (2012). Targeting the HGF/Met signaling pathway in cancer therapy. Expert. Opin. Ther. Targets 16, 553–572.10.1517/14728222.2012.680957Search in Google Scholar PubMed PubMed Central

de Veer, S.J., Swedberg, J.E., Parker, E.A., and Harris, J.M. (2012). Non-combinatorial library screening reveals subsite cooperativity and identifies new high-efficiency substrates for kallikrein-related peptidase 14. Biol. Chem. 393, 331–341.10.1515/bc-2011-250Search in Google Scholar PubMed

Dong, Y., Harrington, B.S., Adams, M.N., Wortmann, A., Stephenson, S.A., Lisle, J., Herington, A., Hooper, J.D., and Clements, J.A. (2014). Activation of membrane-bound proteins and receptor systems: a link between tissue kallikrein and the KLK-related peptidases. Biol. Chem. 395, 977–990.10.1515/hsz-2014-0147Search in Google Scholar PubMed

Fan, B., Wu, T.D., Li, W., and Kirchhofer, D. (2005). Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin. J. Biol. Chem. 280, 34513–34520.10.1074/jbc.M502119200Search in Google Scholar PubMed

Felber, L.M., Borgono, C.A., Cloutier, S.M., Kundig, C., Kishi, T., Ribeiro Chagas, J., Jichlinski, P., Gygi, C.M., Leisinger, H.J., Diamandis, E.P., et al. (2005). Enzymatic profiling of human kallikrein 14 using phage-display substrate technology. Biol. Chem. 386, 291–298.10.1515/BC.2005.035Search in Google Scholar PubMed

Gupta, A., Karakiewicz, P.I., Roehrborn, C.G., Lotan, Y., Zlotta, A.R., and Shariat, S.F. (2008). Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin. Cancer Res. 14, 7385–7390.10.1158/1078-0432.CCR-07-5110Search in Google Scholar PubMed

Hashimoto, T., Kato, M., Shimomura, T., and Kitamura, N. (2010). TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor. FEBS J. 277, 4888–4900.10.1111/j.1742-4658.2010.07894.xSearch in Google Scholar PubMed

Herter, S., Piper, D.E., Aaron, W., Gabriele, T., Cutler, G., Cao, P., Bhatt, A.S., Choe, Y., Craik, C.S., Walker, N., et al. (2005). Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem. J. 390, 125–136.10.1042/BJ20041955Search in Google Scholar PubMed PubMed Central

Hooper, J.D., Bui, L.T., Rae, F.K., Harvey, T.J., Myers, S.A., Ashworth, L.K., and Clements, J.A. (2001). Identification and characterization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle. Genomics 73, 117–122.10.1006/geno.2000.6490Search in Google Scholar PubMed

Ihara, S., Miyoshi, E., Ko, J.H., Murata, K., Nakahara, S., Honke, K., Dickson, R.B., Lin, C.Y., and Taniguchi, N. (2002). Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1–6 GlcNAc branching. J. Biol. Chem. 277, 16960–16967.10.1074/jbc.M200673200Search in Google Scholar PubMed

Ihara, S., Miyoshi, E., Nakahara, S., Sakiyama, H., Ihara, H., Akinaga, A., Honke, K., Dickson, R.B., Lin, C.Y., and Taniguchi, N. (2004). Addition of beta1–6 GlcNAc branching to the oligosaccharide attached to Asn 772 in the serine protease domain of matriptase plays a pivotal role in its stability and resistance against trypsin. Glycobiology 14, 139–146.10.1093/glycob/cwh013Search in Google Scholar PubMed

Ito, Y., Akinaga, A., Yamanaka, K., Nakagawa, T., Kondo, A., Dickson, R.B., Lin, C.Y., Miyauchi, A., Taniguchi, N., and Miyoshi, E. (2006). Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues – its possible role in prolonged stability in vivo by aberrant glycosylation. Glycobiology 16, 368–374.10.1093/glycob/cwj084Search in Google Scholar PubMed

Jacobsen, F., Ashtiani, S.N., Tennstedt, P., Heinzer, H., Simon, R., Sauter, G., Sirma, H., Tsourlakis, M.C., Minner, S., Schlomm, T., et al. (2013). High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. Exp. Ther. Med. 5, 102–106.10.3892/etm.2012.764Search in Google Scholar PubMed PubMed Central

Jameson, G.W., Roberts, D.V., Adams, R.W., Kyle, W.S., and Elmore, D.T. (1973). Determination of the operational molarity of solutions of bovine alpha-chymotrypsin, trypsin, thrombin and factor Xa by spectrofluorimetric titration. Biochem. J. 131, 107–117.10.1042/bj1310107Search in Google Scholar PubMed PubMed Central

Kataoka, H., Itoh, H., Nuki, Y., Hamasuna, R., Naganuma, S., Kitamura, N., and Shimomura, T. (2002). Mouse hepatocyte growth factor (HGF) activator inhibitor type 2 lacking the first Kunitz domain potently inhibits the HGF activator. Biochem. Biophys. Res. Commun. 290, 1096–1100.10.1006/bbrc.2001.6313Search in Google Scholar PubMed

Kawaguchi, M. and Kataoka, H. (2014). Mechanisms of hepatocyte growth factor activation in cancer tissues. Cancers (Basel) 6, 1890–1904.10.3390/cancers6041890Search in Google Scholar PubMed PubMed Central

Kirchhofer, D., Peek, M., Li, W., Stamos, J., Eigenbrot, C., Kadkhodayan, S., Elliott, J.M., Corpuz, R.T., Lazarus, R.A., and Moran, P. (2003). Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J. Biol. Chem. 278, 36341–36349.10.1074/jbc.M304643200Search in Google Scholar PubMed

Kirchhofer, D., Peek, M., Lipari, M.T., Billeci, K., Fan, B., and Moran, P. (2005). Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett. 579, 1945–1950.10.1016/j.febslet.2005.01.085Search in Google Scholar PubMed

Kiyomiya, K., Lee, M.S., Tseng, I.C., Zuo, H., Barndt, R.J., Johnson, M.D., Dickson, R.B., and Lin, C.Y. (2006). Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells. Am. J. Physiol. Cell Physiol. 291, C40–C49.10.1152/ajpcell.00351.2005Search in Google Scholar PubMed

Lee, S.L., Dickson, R.B., and Lin, C.Y. (2000). Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 275, 36720–36725.10.1074/jbc.M007802200Search in Google Scholar PubMed

Lin, C.Y., Anders, J., Johnson, M., and Dickson, R.B. (1999). Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J. Biol. Chem. 274, 18237–18242.10.1074/jbc.274.26.18237Search in Google Scholar PubMed

Miyake, Y., Tsuzuki, S., Mochida, S., Fushiki, T., and Inouye, K. (2010). The role of asparagine-linked glycosylation site on the catalytic domain of matriptase in its zymogen activation. Biochim. Biophys. Acta 1804, 156–165.10.1016/j.bbapap.2009.09.025Search in Google Scholar PubMed

Miyazawa, K. (2010). Hepatocyte growth factor activator (HGFA): a serine protease that links tissue injury to activation of hepatocyte growth factor. FEBS J. 277, 2208–2214.10.1111/j.1742-4658.2010.07637.xSearch in Google Scholar PubMed

Mukai, S., Fukushima, T., Naka, D., Tanaka, H., Osada, Y., and Kataoka, H. (2008). Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases. FEBS J. 275, 1003–1017.10.1111/j.1742-4658.2008.06265.xSearch in Google Scholar PubMed

Nagakawa, O., Yamagishi, T., Akashi, T., Nagaike, K., and Fuse, H. (2006). Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer. Prostate 66, 447–452.10.1002/pros.20301Search in Google Scholar PubMed

Nakashiro, K., Hayashi, Y., and Oyasu, R. (2003). Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. Oncol. Rep. 10, 1149–1153.10.3892/or.10.5.1149Search in Google Scholar

Oberst, M.D., Williams, C.A., Dickson, R.B., Johnson, M.D., and Lin, C.Y. (2003). The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J. Biol. Chem. 278, 26773–26779.10.1074/jbc.M304282200Search in Google Scholar PubMed

Oikonomopoulou, K., Hansen, K.K., Saifeddine, M., Tea, I., Blaber, M., Blaber, S.I., Scarisbrick, I., Andrade-Gordon, P., Cottrell, G.S., Bunnett, N.W., et al. (2006). Proteinase-activated receptors, targets for kallikrein signaling. J. Biol. Chem. 281, 32095–32112.10.1074/jbc.M513138200Search in Google Scholar PubMed

Owen, K.A., Qiu, D., Alves, J., Schumacher, A.M., Kilpatrick, L.M., Li, J., Harris, J.L., and Ellis, V. (2010). Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem. J. 426, 219–228.10.1042/BJ20091448Search in Google Scholar PubMed

Prassas, I., Eissa, A., Poda, G., and Diamandis, E.P. (2015). Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat. Rev. Drug. Discov. 14, 183–202.10.1038/nrd4534Search in Google Scholar PubMed

Rabien, A., Fritzsche, F., Jung, M., Diamandis, E.P., Loening, S.A., Dietel, M., Jung, K., Stephan, C., and Kristiansen, G. (2008). High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse. Tumour. Biol. 29, 1–8.10.1159/000132565Search in Google Scholar PubMed

Rajapakse, S. and Takahashi, T. (2007). Expression and enzymatic characterization of recombinant human kallikrein 14. Zoolog. Sci. 24, 774–780.10.2108/zsj.24.774Search in Google Scholar PubMed

Ramsay, A.J., Dong, Y., Hunt, M.L., Linn, M., Samaratunga, H., Clements, J.A., and Hooper, J.D. (2008). Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. J. Biol. Chem. 283, 12293–12304.10.1074/jbc.M709493200Search in Google Scholar PubMed

Sanchez, W.Y., de Veer, S.J., Swedberg, J.E., Hong, E.J., Reid, J.C., Walsh, T.P., Hooper, J.D., Hammond, G.L., Clements, J.A., and Harris, J.M. (2012). Selective cleavage of human sex hormone-binding globulin by kallikrein-related peptidases and effects on androgen action in LNCaP prostate cancer cells. Endocrinology 153, 3179–3189.10.1210/en.2012-1011Search in Google Scholar PubMed

Shia, S., Stamos, J., Kirchhofer, D., Fan, B., Wu, J., Corpuz, R.T., Santell, L., Lazarus, R.A., and Eigenbrot, C. (2005). Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J. Mol. Biol. 346, 1335–1349.10.1016/j.jmb.2004.12.048Search in Google Scholar PubMed

Skropeta, D. (2009). The effect of individual N-glycans on enzyme activity. Bioorg. Med. Chem. 17, 2645–2653.10.1016/j.bmc.2009.02.037Search in Google Scholar PubMed

Stefansson, K., Brattsand, M., Ny, A., Glas, B., and Egelrud, T. (2006). Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum. Biol. Chem. 387, 761–768.10.1515/BC.2006.095Search in Google Scholar PubMed

Strohmeyer, D., Strauss, F., Rossing, C., Roberts, C., Kaufmann, O., Bartsch, G., and Effert, P. (2004). Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res. 24, 1797–1804.Search in Google Scholar

Tsai, C.H., Teng, C.H., Tu, Y.T., Cheng, T.S., Wu, S.R., Ko, C.J., Shyu, H.Y., Lan, S.W., Huang, H.P., Tzeng, S.F., et al. (2014). HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase. Oncogene 33, 4643–4652.10.1038/onc.2013.412Search in Google Scholar PubMed PubMed Central

Trusolino, L., Bertotti, A., and Comoglio, P.M. (2010). MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11, 834–848.10.1038/nrm3012Search in Google Scholar PubMed

Varkaris, A., Corn, P.G., Gaur, S., Dayyani, F., Logothetis, C.J., and Gallick, G.E. (2011). The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert. Opin. Investig. Drugs 20, 1677–1684.10.1517/13543784.2011.631523Search in Google Scholar PubMed PubMed Central

Warren, M., Twohig, M., Pier, T., Eickhoff, J., Lin, C.Y., Jarrard, D., and Huang, W. (2009). Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis. Appl. Immunohistochem. Mol. Morphol. 17, 23–30.10.1097/PAI.0b013e31817c3334Search in Google Scholar PubMed

Yasuda, K., Nagakawa, O., Akashi, T., Fujiuchi, Y., Koizumi, K., Komiya, A., Saiki, I., and Fuse, H. (2009). Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. Prostate 69, 346–351.10.1002/pros.20890Search in Google Scholar PubMed

Yasuda, K., Komiya, A., Watanabe, A., Morii, A., Oya, T., Nagakawa, O., Fujiuchi, Y., and Fuse, H. (2013). Expression of Hepatocyte growth factor activator inhibitor type-1 (HAI-1) in prostate cancer. Anticancer Res. 33, 575–581.10.1016/j.urology.2011.07.917Search in Google Scholar

Yousef, G.M., Magklara, A., Chang, A., Jung, K., Katsaros, D., and Diamandis, E.P. (2001). Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res. 61, 3425–3431.Search in Google Scholar